OBJECTIVE: To determine the effect of oral contraceptives (OC) on hamstring neuromechanics and lower extremity stiffness across the menstrual cycle (MC). DESIGN: Causal comparative. SETTING: Research laboratory. PARTICIPANTS: Thirty, healthy, normally menstruating female volunteers who were using OC (OC group, n = 15) or not (non-OC group, n = 15). ASSESSMENT OF RISK FACTORS: Stiffness and hamstring neuromechanics were assessed at 2 points of the MC corresponding to low (menses) and high (ovulation) hormone concentrations. Menses testing took place 3 to 5 days after the onset of menses (or pills 3-5 for the OC group). Ovulation test session occurred 2 to 4 days after ovulation identified using a commercial ovulation kit (or pills 15-17 in the OC group). MAIN OUTCOME MEASURES: Lower extremity stiffness and hamstring neuromechanics [stiffness, electromechanical delay, rate of force production (RFP), time to 50% peak force (T50%)] and blood plasma concentrations of estradiol-β-17, free testosterone, and progesterone. RESULTS: Estradiol-β-17, free testosterone, and progesterone increased at ovulation in the non-OC group and remained constant in the OC group. No changes were observed across the MC or between the groups in other variables (P > 0.05). CONCLUSIONS: Although previous literature suggests a prophylactic effect of OC use with respect to musculoskeletal injury risk, our results indicate that OC use does not affect muscle properties in manners thought to reduce ACL injury risk.
OBJECTIVE: To determine the effect of oral contraceptives (OC) on hamstring neuromechanics and lower extremity stiffness across the menstrual cycle (MC). DESIGN: Causal comparative. SETTING: Research laboratory. PARTICIPANTS: Thirty, healthy, normally menstruating female volunteers who were using OC (OC group, n = 15) or not (non-OC group, n = 15). ASSESSMENT OF RISK FACTORS: Stiffness and hamstring neuromechanics were assessed at 2 points of the MC corresponding to low (menses) and high (ovulation) hormone concentrations. Menses testing took place 3 to 5 days after the onset of menses (or pills 3-5 for the OC group). Ovulation test session occurred 2 to 4 days after ovulation identified using a commercial ovulation kit (or pills 15-17 in the OC group). MAIN OUTCOME MEASURES: Lower extremity stiffness and hamstring neuromechanics [stiffness, electromechanical delay, rate of force production (RFP), time to 50% peak force (T50%)] and blood plasma concentrations of estradiol-β-17, free testosterone, and progesterone. RESULTS: Estradiol-β-17, free testosterone, and progesterone increased at ovulation in the non-OC group and remained constant in the OC group. No changes were observed across the MC or between the groups in other variables (P > 0.05). CONCLUSIONS: Although previous literature suggests a prophylactic effect of OC use with respect to musculoskeletal injury risk, our results indicate that OC use does not affect muscle properties in manners thought to reduce ACL injury risk.
Authors: David R Bell; J Troy Blackburn; Anthony C Hackney; Stephen W Marshall; Anthony I Beutler; Darin A Padua Journal: J Athl Train Date: 2014-02-25 Impact factor: 2.860
Authors: Kirsty J Elliott-Sale; Kelly L McNulty; Paul Ansdell; Stuart Goodall; Kirsty M Hicks; Kevin Thomas; Paul A Swinton; Eimear Dolan Journal: Sports Med Date: 2020-10 Impact factor: 11.136
Authors: Kelly Lee McNulty; Kirsty Jayne Elliott-Sale; Eimear Dolan; Paul Alan Swinton; Paul Ansdell; Stuart Goodall; Kevin Thomas; Kirsty Marie Hicks Journal: Sports Med Date: 2020-10 Impact factor: 11.136